Cingulate Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 13, 2026, reporting an expanded operating loss and a significant increase in cash and cash equivalents compared to year-end 2025.

Key Highlights

  • Cash position: Cash and cash equivalents rose to $23,185,900 as of September 30, 2026, up from $10,953,383 at December 31, 2025, according to the filing.
  • Operating loss (nine months): The company reported an operating loss of $20,829,215 for the nine months ended September 30, 2026, compared to $14,351,844 for the same period in 2025.
  • Operating loss (quarter): For the three months ended September 30, 2026, the operating loss was $7,491,018, versus $5,995,835 in the prior-year quarter.
  • Accumulated deficit: The accumulated deficit reached $155,288,781 as of September 30, 2026, up from $132,375,031 at December 31, 2025.
  • Shares outstanding: As of November 13, 2026, 14,963,080 shares of common stock were issued and outstanding, compared to 7,250,299 shares at December 31, 2025.
  • Total stockholders' equity: Total stockholders' equity improved to $20,767,130 at September 30, 2026, from $2,508,907 at December 31, 2025.
  • Note payable reduced: The current note payable declined to $3,372,073 at September 30, 2026, from $6,295,960 at December 31, 2025, with the long-term note payable reduced to zero from $1,151,509.

Cingulate's Financial Position and Results for the Quarter Ended September 30, 2026

Cingulate Inc. (NASDAQ:CING), a smaller reporting company and emerging growth company incorporated in Delaware, disclosed its unaudited consolidated financial results for the three and nine months ended September 30, 2026. According to the filing, total assets increased to $28,150,677 at September 30, 2026, compared to $15,073,263 at December 31, 2025, driven primarily by the growth in cash and cash equivalents. Total liabilities fell to $7,383,547 from $12,564,356 over the same period, the filing stated.

On the income statement, the company reported research and development expenses of $2,910,660 for the three months ended September 30, 2026, compared to $2,848,544 in the prior-year quarter. Selling, general and administrative expenses increased to $4,580,358 in the third quarter of 2026 from $3,147,291 in the third quarter of 2025. For the nine months ended September 30, 2026, selling, general and administrative expenses totaled $14,247,412, up from $6,579,735 in the same period of 2025, according to the filing.

The loss before income taxes for the nine-month period was $22,913,750, compared to $16,177,001 for the nine months ended September 30, 2025. The filing also noted a change in fair value of derivatives of negative $1,235,366 for the nine months ended September 30, 2026. Common stock authorized totals 240,000,000 shares at $0.0001 par value, and preferred stock authorized totals 10,000,000 shares, with zero preferred shares issued or outstanding at either balance sheet date. The company's forward-looking statements in the filing are subject to its own cautionary language regarding risks and uncertainties.

What Was Disclosed

Cingulate Inc. filed a Form 10-Q for the quarter ended September 30, 2026, disclosing unaudited financial statements showing increased cash, a wider operating loss, reduced total liabilities, and a substantial increase in shares outstanding compared to December 31, 2025.